Essays on the science, the strategy, and the lived experience of the 18 months after.
Cutting Edge
2026 ResearchThe Maintenance Dose Question: Tapered Off vs. Microdose
STEP-Maintain and TIDE-2 are testing ultra-low maintenance dosing — and reshaping what a successful exit looks like.
Why Bone Density Loss Is the Quiet Cost of GLP-1 Treatment
2026 DEXA cohort data is documenting BMD loss most acute in perimenopausal women. What the maintenance phase has to do about it.
The Microbiome Reset: What Happens to Your Gut After Stopping Ozempic
2026 metagenomics studies are mapping how GLP-1s reshape the gut — and what reverts vs. persists after discontinuation.
Food Noise Has a Brain Signature: fMRI Studies and the Rebound
2026 neuroimaging mapped which brain regions go quiet on GLP-1s — and which re-activate during the rebound.
The Compounded Semaglutide Crackdown — What 2026 Means for Women Forced Off
FDA enforcement is reshaping the compounded GLP-1 market. The regulatory map and what to do if you’re in the gap.
Cardiovascular Benefits That Stay (And the Ones That Don’t)
The SELECT trial’s long-term follow-up data shows which CV protections persist after discontinuation. The “was it worth it” answer.
Why the Mediterranean Diet Specifically Reduces Post-GLP-1 Regain
MEDI-MAINT compared four dietary patterns in post-GLP-1 maintenance. Mediterranean outperformed by a meaningful margin.
The Retatrutide Question: What the Triple-Agonist Trials Mean Today
Retatrutide is 12-24 months from market. The trial data is striking. The question: wait, or proceed?
Sleep Architecture After Ozempic: 2026 Polysomnography Findings
First detailed polysomnography studies of post-GLP-1 sleep. Women’s sleep changes substantially — in ways most clinicians don’t track.
Pharmacogenomics and Your Personal Regain Risk: First Predictive Markers
2026 research is identifying the first genetic markers that predict who maintains vs. regains. The science is real. The clinical limits are real too.
Foundations
The canonWhat Happens to Your Body the First 30 Days After Stopping Ozempic
Week-by-week: ghrelin rebound, insulin sensitivity shifts, where the regain typically starts — and what to do at each step.
Why You’re Hungrier Than Before You Started the Drug
The ghrelin rebound is real, and it’s louder than your pre-drug baseline. Four specific tactics to manage it.
The 4x Faster Regain: What the Cambridge Study Actually Said
Plain-language breakdown of the 2026 meta-analyses. What “4x faster” means in pounds-per-month, and why it’s fixable.
Why Most Coaches Won’t Touch GLP-1 Clients
The coaching industry has been avoiding medicated clients for two years. We built WeWontRegain because of that gap.
The Muscle Mass Problem Nobody Warned You About
Up to 40% of GLP-1 weight loss can be lean mass. In perimenopause, that’s a five-alarm fire. Here’s the rebuild protocol.
Tapering vs Quitting Cold Turkey: Which One Is Actually Safer?
Neither matters as much as what you do in the 18 months after. But the exit method does shift the early protocol.
Perimenopause + Post-Ozempic: The Double Storm Nobody’s Mapping
Two simultaneous metabolic shifts. Why standard menopause coaching misses this, and what an integrated approach looks like.
The Shame Question: Why You Felt Judged for Taking the Drug
The “easy way out” judgment is a public health issue. Reframing the work that actually comes next.
What to Eat in the First Week After Your Last Dose
Structure beats willpower. Protein targets, fiber timing, and a 3-day eating framework for the acute window.
The 18-Month Window: Why Year 2 Off the Drug Matters Most
12-week programs aren’t designed for an 18-month problem. Why most regain locks in between month 12 and 18.
Reading is the warm-up. The 1:1 is the work.
If any of these essays describes your situation, the consult is the next move. Fifteen minutes, no sales pitch.
Schedule Your Free Consult →